Cytovance Biologics, Inc. announces Bexion Pharmaceuticals Inc. has chosen Cytovance to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350
28. November 2017 05:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance), a leading full-service contract development and manufacturer of mammalian and microbial biologics, today...